A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COMBINATION WITH PACLITAXEL CARBOPLATIN AND BEVACIZUMAB FOR PATIENTS WITH NEWLY DIAGNOSED STAGE III/IV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
Brief description of study
If you have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer, you may qualify for this study. The goal of this phase III study is to research the effects, good or bad, of investigational drug atezolizumab on your specific type of cancer (ovarian, fallopian tube, or primary peritoneal) when combined with chemotherapy-based treatments that are standard for patients with your specific type of cancer.
Clinical Study Identifier: s16-01882
ClinicalTrials.gov Identifier: NCTs16-01882
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
